组蛋白去乙酰化酶SIRT6在乳腺癌中的研究进展  

Research progress of histone deacetylase SIRT6 in breast cancer

作　　者：覃庆洪[1] Qin Qinghong(Department of Breast Surgery,The Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院乳腺外科,南宁530021

出　　处：《广西医科大学学报》2021年第6期1218-1222,共5页Journal of Guangxi Medical University

基　　金：广西自然科学基金面上项目资助(No.2019GXNSFAA245067)。

摘　　要：SIRT6属于Ⅲ型组蛋白去乙酰化酶,具有去乙酰化酶活性和单ADP核糖基转移酶活性,通过促进基因修复、调控转录、影响代谢、调节炎症等参与许多病理、生理过程,在肿瘤的发生、发展以及化疗耐药性中发挥重要作用。本文将从SIRT6在乳腺癌发生、发展以及耐药性等方面的作用,阐述SIRT6与乳腺癌的关系,进一步了解乳腺癌的病理机制以及治疗现状。SIRT6 is type Ⅲ histone deacetylase with deacetylase activity and ADP-ribosyltransferase activity.SIRT6 involves in many pathological and physiological processes such as promoting gene repair, regulating transcription, influencing metabolism and regulating inflammation.It plays an important role in the occurrence and development of tumors as well as chemotherapy resistance. This paper elucidates the relationship between SIRT6 and breast cancer from the role of SIRT6 in the occurrence and development of breast cancer as well as drug resistance, etc., so as to further understand the pathological mechanism and treatment status of breast cancer.

关 键 词：SIRT6 乳腺癌 发生 进展 耐药 

分 类 号：R737.9[医药卫生—肿瘤]